US Merck Products

 

Showing   of   Products

#00857c

(suvorexant) 5, 10, 15, 20 mg tablets, for oral use, C-IV

    #00857c

    (sugammadex) injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium), for intravenous use

      #00857c

      (fidaxomicin) tablets 200 mg | oral suspension 200 mg/5 ml

        #00857c

        ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use

          #00857c

          JANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets

            Before prescribing JANUMET or JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

            #00857c

            (sitagliptin) 25 mg, 50 mg, 100 mg tablets

              #00857c

              PIFELTRO® (doravirine 100 mg) tablets and DELSTRIGO® (doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets

                Before prescribing PIFELTRO, please read the accompanying Prescribing Information. The Patient Information also is available.

                 

                Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B. The Patient Information also is available.

                #00857c

                (letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL

                  #00857c

                  (imipenem, cilastatin, and relebactam) for injection 1.25 g

                    #00857c

                    (ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets

                      Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

                      #00857c

                      (tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use

                        #00857c

                        (ertugliflozin) 5 mg, 15 mg tablets

                          #00857c

                          (ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets

                            #00857c

                            (vericiguat) tablets 2.5 mg, 5 mg, 10 mg

                              Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

                              #00857c

                              (belzutifan) 40 mg tablets

                                Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

                                #00857C

                                (sotatercept-csrk) for injection 45 mg, 60 mg

                                  #00857c

                                  (ceftolozane and tazobactam) for injection (1.5 g), for intravenous use

                                    #00857c

                                    (bezlotoxumab) injection 25 mg/mL